Drug Profile
Nepicastat oral- Acorda Therapeutics
Alternative Names: APL-1401; DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Asieris Pharmaceuticals; Biotie Therapies Corp.
- Class Anti-inflammatories; Antineoplastics; Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
- Mechanism of Action Dopamine beta hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ulcerative colitis
- Preclinical Unspecified
- Discontinued Autoimmune disorders; Cancer; Cocaine-related disorders; Parkinson's disease; Post-traumatic stress disorders